Abstract
A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) administered every 3 weeks to previously untreated locally advanced or metastatic breast cancer patients. In 119 patients evaluable for therapeutic response, complete plus partial response rate was 44% for CNF and 29% for CMF (p > 0.05; 95% C.I.: CNF = 32%-56%, CMF = 18%-40%). No statistically significant difference regarding time to progression, overall survival or response to second-line chemotherapy with Epidoxorubicin was observed between the two regimens. Both regimens were well tolerated, but the percent of alopecia and leucopenia was significantly higher in the CNF patient group (31% versus 5% and 18% versus 0%, respectively; p <0.01). In conclusion, CNF was demonstrated to be slightly more toxic but more effective as compared to CMF (global response: 44% versus 29%, respectively). These findings should be taken into consideration when planning future studies of adjuvant chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 531-535 |
| Number of pages | 5 |
| Journal | International Journal of Oncology |
| Volume | 2 |
| Issue number | 4 |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
Cite this
Combination chemotherapy withy CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil, cyclophosphamide) in advanced breast cancer : A multicer randomized study. / Lorusso, V.; Vici, P.; Bianco, A. R.; Lopez, M.; De Placido, S.; Piano, A.; Palomba, G.; Carlomagno, C.; D'Aprile, M.; Fosser, V.; Brandi, M.; De Lena, M.
In: International Journal of Oncology, Vol. 2, No. 4, 1993, p. 531-535.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination chemotherapy withy CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil, cyclophosphamide) in advanced breast cancer
T2 - A multicer randomized study
AU - Lorusso, V.
AU - Vici, P.
AU - Bianco, A. R.
AU - Lopez, M.
AU - De Placido, S.
AU - Piano, A.
AU - Palomba, G.
AU - Carlomagno, C.
AU - D'Aprile, M.
AU - Fosser, V.
AU - Brandi, M.
AU - De Lena, M.
PY - 1993
Y1 - 1993
N2 - A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) administered every 3 weeks to previously untreated locally advanced or metastatic breast cancer patients. In 119 patients evaluable for therapeutic response, complete plus partial response rate was 44% for CNF and 29% for CMF (p > 0.05; 95% C.I.: CNF = 32%-56%, CMF = 18%-40%). No statistically significant difference regarding time to progression, overall survival or response to second-line chemotherapy with Epidoxorubicin was observed between the two regimens. Both regimens were well tolerated, but the percent of alopecia and leucopenia was significantly higher in the CNF patient group (31% versus 5% and 18% versus 0%, respectively; p <0.01). In conclusion, CNF was demonstrated to be slightly more toxic but more effective as compared to CMF (global response: 44% versus 29%, respectively). These findings should be taken into consideration when planning future studies of adjuvant chemotherapy.
AB - A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) administered every 3 weeks to previously untreated locally advanced or metastatic breast cancer patients. In 119 patients evaluable for therapeutic response, complete plus partial response rate was 44% for CNF and 29% for CMF (p > 0.05; 95% C.I.: CNF = 32%-56%, CMF = 18%-40%). No statistically significant difference regarding time to progression, overall survival or response to second-line chemotherapy with Epidoxorubicin was observed between the two regimens. Both regimens were well tolerated, but the percent of alopecia and leucopenia was significantly higher in the CNF patient group (31% versus 5% and 18% versus 0%, respectively; p <0.01). In conclusion, CNF was demonstrated to be slightly more toxic but more effective as compared to CMF (global response: 44% versus 29%, respectively). These findings should be taken into consideration when planning future studies of adjuvant chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0027178325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027178325&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0027178325
VL - 2
SP - 531
EP - 535
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 4
ER -